

Benzoquinones and Terphenyl Compounds As Phosphodiesterase-4B Inhibitors from a Fungus of the Order Chaetothyriales (MSX 47445)

By: Tamam El-Elimat, [Mario Figueroa](#), [Huzefa A. Raja](#), [Tyler N. Graf](#), Audrey F. Adcock, David J. Kroll, Cynthia S. Day, Mansukh C. Wani, [Cedric J. Pearce](#), and [Nicholas H. Oberlies](#)

El-Elimat T., Figueroa M., Raja, H.A., Graf T., Adcock A., Kroll D., Wani M.C., Pearce C., . 2013. Benzoquinones and Terphenyl Compounds as Phosphodiesterase-4B Inhibitors from a Fungus of the Order Chaetothyriales (MSX 47445). *Journal of Natural Products* 76: 382–387.

Made available courtesy of American Chemical Society:


<http://dx.doi.org/10.1021/np300749w>

***© American Chemical Society. Reprinted with permission. No further reproduction is authorized without written permission from American Chemical Society. This version of the document is not the version of record. Figures and/or pictures may be missing from this format of the document. ***

This is an unofficial adaptation of an article that appeared in an ACS publication. ACS has not endorsed the content of this adaptation or the context of its use.

Abstract:

Three bioactive compounds were isolated from an organic extract of an ascomycete fungus of the order Chaetothyriales (MSX 47445) using bioactivity-directed fractionation as part of a search for anticancer leads from filamentous fungi. Of these, two were benzoquinones [betulinan A (1) and betulinan C (3)], and the third was a terphenyl compound, BTH-II0204-207:A (2). The structures were elucidated using a set of spectroscopic and spectrometric techniques; the structure of the new compound (3) was confirmed via single-crystal X-ray diffraction. Compounds 1–3 were evaluated for cytotoxicity against a human cancer cell panel, for antimicrobial activity against *Staphylococcus aureus* and *Candida albicans*, and for phosphodiesterase (PDE4B2) inhibitory activities. The putative binding mode of 1–3 with PDE4B2 was examined using a validated docking protocol, and the binding and enzyme inhibitory activities were correlated.



Keywords: fungi | cancer | betulinan A (1) | betulinan C (3) | BTH-II0204-207:A (2)

Article:

Historically, natural products have played an important role in drug discovery. Of the 1355 newly approved drugs worldwide during the time period of 1981–2010, ~50% can be traced to, or were inspired by, natural products.(1) Moreover, of the 13 natural product-derived drugs that were approved in the U.S. between 2005 and 2007, five were the first members of new classes,(2) and in 2010, fingolimod, an analogue of the fungal metabolite myriocin, was approved as the first oral drug to reduce multiple sclerosis relapses.(3) In July of 2012, carfilzomib, an analogue of the natural product epoxomicin, which was isolated originally from an Actinomycete,(4) was approved to treat patients with multiple myeloma.(5) In short, natural products remain an invaluable source for novel bioactive leads.


As part of a multidisciplinary project to identify structurally diverse anticancer leads,(6, 7) the Mycosynthetix library, representing over 55 000 accessions of filamentous fungi, is being examined systematically.(8-12) Fungi represent an underexplored source for bioactive secondary metabolites. In 1991, the number of fungi was estimated as 1.5 million species,(13) while current estimates suggest more than 5.1 million species.(14) Regardless, fewer than 100 000 species have been characterized taxonomically,(14) with likely a smaller percentage studied for bioactive secondary metabolites, and only a portion of these have been evaluated for anticancer activity.

An organic fraction of the filamentous fungus MSX 47445,(9) which was isolated from highly decomposed woody debris from a tropical forest in 1990, displayed modest but equipotent cytotoxic activity against a panel of three cancer cell lines: MCF-7, H460, and SF268 (~75% inhibition of cell growth when tested at 20 µg/mL). Hence, this fungus was selected for further study, and three compounds, two benzoquinones (1 and 3) and one terphenyl compound (2), were isolated and characterized. All three compounds were evaluated for cytotoxicity against a human cancer cell panel, for antimicrobial activity against *Staphylococcus aureus* and *Candida albicans*, and for their phosphodiesterase (PDE4B2) inhibitory activities; the results with the latter were the most encouraging and led to docking studies.

Result and Discussion

A solid-phase culture of MSX 47445 was extracted with 1:1 CHCl₃–MeOH and partitioned with organic solvents to yield an orange-red extract, which was purified using flash chromatography to yield seven fractions. Of these, fraction 2 was the most cytotoxic against three cancer cell lines, and it was subjected to further purifications using preparative and semipreparative HPLC to yield three compounds (1–3) with >97% purity as measured by UPLC (Supporting Information Figure S1).

Compound 1 (30.2 mg) was obtained as an orange powder. The molecular formula was determined as C₂₀H₁₆O₄ by HRESIMS. The NMR data, in conjunction with HRMS data and UV maxima of 194, 238, and 320 nm, identified 1 as the known compound betulinan A, first described by Lee et al.(15) in 1996 from the fungus *Lenzites betulina*.



Compound 2 (12.1 mg) was obtained as a pale yellow powder. HRESIMS data suggested a molecular formula of $C_{19}H_{16}O_3$. The compound showed distinctive UV maxima at 202, 259, and 315 nm. The NMR data were in agreement with those reported for BTH-II0204-207:A, a terphenyl compound first reported in 2011 by Beggins et al.(16) from the pathogenic bacterium *Burkholderia pseudomallei*.

Compound 3 (6.2 mg) was obtained as an orange powder. The molecular formula was determined as $C_{19}H_{14}O_3$ via HRESIMS, establishing an index of hydrogen deficiency of 13. The UV maxima (198, 235, and 331 nm) and NMR data suggested structural similarity with compound 1, although a key difference was the loss of structural symmetry. Relative to 1, compound 3 also lacked one methoxy moiety, as supported by a 30 amu difference in the HRMS data. 1H NMR data (Table 1) revealed the presence of 10 aromatic protons (δ_H 7.45–7.52 for H-2' to H-6' and δ_H 7.33–7.42 for H-2'' to H-6''), suggesting two monosubstituted benzene rings, one olefinic proton (δ_H 6.88, H-6), and one methoxy group (δ_H 3.80, 3-OCH₃). The ^{13}C NMR data revealed the presence of 19 carbons, consistent with the molecular formula and indicative of two carbonyls, which were assigned as quinone carbons (δ_C 187.4 and 183.3, for C-1 and C-4, respectively), four olefinic carbons (δ_C 132.7, 155.4, 144.5, and 133.0, for C-2, C-3, C-5, and C-6, respectively), and 10 aromatic carbons (δ_C 130.7, 128.2, 129.0, 128.2, 130.7, 129.4, 128.8, 130.3, 128.8, and 129.4, for C-2', C-3', C-4', C-5', C-6', C-2'', C-3'', C-4'', C-5'', and C-6'', respectively). Thus far, the spectroscopic data accounted for 12 of the 13 degrees of unsaturation, and hence, the 13th degree completed the quinone ring. COSY data identified two spin systems, which corresponded to the aromatic protons of the two phenyl rings. An HMBC correlation was observed from 3-OCH₃ to C-3, indicating the connectivity of the methoxy group. HMBC correlations from H-6 to C-4, C-2, and C-1' were observed. NOESY correlations were observed

from the olefinic proton H-6 to the equivalent C-2'/C-6' and from the 3-OCH₃ to the equivalent C-2''/C-6'' (Figure 1b). The last structure elucidation hurdle was to verify whether the central ring was an ortho or para quinone, but the spectroscopic data were inconclusive, since the observed HMBC and NOESY correlations for the H-3 and the 3-OCH₃ were equally valid for either substitution pattern. What increased the dilemma of the substitution pattern were contradictory NMR data that were published by two different research groups for a synthetic(17) and a natural(18) compound with the same molecular formula (compound 4). Our NMR data were in agreement with those reported by Singh and co-workers, except for one carbon where the ¹³C NMR data differed by about 12 ppm.(18) Sawayama et al.(17) reported the synthesis of 4, where clear differences were observed between the NMR data of synthetic and natural 4, and they stated that reexamination of the structure of natural 4 was “underway by Dr. S. B. Singh”. However, since this reexamination has not been reported yet, compound 3 was crystallized from ethyl acetate at room temperature to give monoclinic crystals, and single-crystal X-ray diffraction established the structure of 3 with the carbonyl carbons para to each other (Figure 1a). To be consistent with the literature, the trivial name betulinan C was ascribed to 3.

Table 1. ¹H (500 MHz) and ¹³C (125 MHz) NMR Data for Betulinan C (3) in CDCl₃

position	δ _C , type	δ _H (J in Hz)
1	187.4, C	
2	132.7, C	
3	155.4, C	
4	183.3, C	
5	144.5, C	
6	133.0, CH	6.88, s
1'	128.8, C	
2', 6'	129.4, CH	7.52, dd (8.0, 1.7)
3', 5'	128.8, CH	7.45, m
4'	130.3, CH	7.45, m
1''	130.0, C	
2'', 6''	130.7, CH	7.33, dd (8.0, 1.7)
3'', 5''	128.2, CH	7.42, m
4''	129.0, CH	7.40, m
3-OCH ₃	61.67, CH ₃	3.80, s




Figure 1. (a) X-ray crystallographic structure with 50% probability ellipsoids. (b) Key HMBC and NOESY correlations of 3.

Compounds structurally related to 1–3 have been identified as phosphodiesterase (PDE) inhibitors. Terferol (5), which was isolated from *Streptomyces showdoensis* SANK 65080, possessed inhibitory activity against cyclic adenosine 3',5'-monophosphate phosphodiesterase (cAMP-PDE) and cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE).⁽¹⁹⁾ The concentrations of 5 required for 50% inhibition of cAMP-PDE and cGMP-PDE were 0.82 and 0.96 μ M, respectively.⁽¹⁹⁾ Moreover, Biggins et al.⁽¹⁶⁾ evaluated two terferol-related compounds, BTH-II0204-207:A (2) and BTH-II0204-207:C, for PDE inhibition activity against 11 PDE families. The latter was inactive, while 2 showed activity against PDE11 as well as four out of the five PDE4s that were examined. PDE4 is an essential regulator of the secondary messenger cAMP in numerous cell types, and the reduction in cAMP degradation by several inhibitors, such as rolipram, piclamilast, roflumilast, cilomilast, and tetomilast, has suggested a broad range of clinical applications for the treatment of asthma and chronic obstructive pulmonary disease (COPD),^(20, 21) some types of brain tumors,^(22, 23) and other inflammatory diseases.⁽²⁴⁾ In 2011, roflumilast (Daliresp) was approved by the U.S. FDA as the first selective PDE4 inhibitor to reduce COPD exacerbations.⁽²⁵⁾ Moreover, abnormal regulation of cAMP and/or cGMP metabolism upon altered expression and activity of PDE isoforms has been implicated in the pathogenesis of various types of cancer, including prostate cancer, colon cancer, hematological malignancies, melanoma, and brain tumors.^(26, 27) On the basis of these reports, the effects of 1–3 on the activity of recombinant human PDE4B⁽²⁸⁾ were evaluated; PDE4B is the predominant isoform present in human monocytes and neutrophils and is involved mainly in inflammation.⁽²⁹⁾ Of these, 3 was the most potent, with an IC₅₀ value of 17 μ M, followed by compounds 2 and 1, with IC₅₀ values of 31 and 44 μ M, respectively (Figure 2; Table 2).




Figure 2. Plots of the effect of compounds 1–3 and rolipram (positive control) on PDE4B2 activity. Substrate conc = 100 nM (cAMP).

Table 2. PDE4B2 Inhibition Activity and Docking Results of Compounds 1–3

compound	PDE4B2 inhibition IC_{50} (μM)	docking score (kcal/mol)	docking score rank
betulinan A (1)	44	-8.071	4
BTH-II0204-207:A (2)	31	-8.277	3
betulinan C (3)	17	-8.732	2
rolipram ^a	0.4	-11.396	1

^aPostive control.

Molecular docking and other computational approaches are being used increasingly to explore the ligand-binding interactions of PDE4 inhibitors.(30-33) As such, compounds 1–3 were docked into the crystal structure of human PDE4B using Glide Extra Precision.(34, 35) The docking protocol was verified by testing its ability to reproduce the experimental binding mode of cocrystallized rolipram (Supporting Information Figure S4). To this end, rolipram bound to the crystal structure was removed from the binding pocket and docked back into the cofactor binding site; the root-mean-square deviation between the predicted conformation and the observed X-ray

crystallographic data was 1.1 Å, indicating the capability of the docking protocol to reproduce the binding mode of rolipram (Supporting Information Figure S4). Compounds 1–3 were docked into the cAMP binding site of PDE4B. The docking scores calculated with Glide correlated with the biological activity (Table 2); compound 3 displayed the highest activity (IC₅₀ value of 17 μM) and also the top-ranked docking score (−8.732 kcal/mol). In contrast, compound 1 had the lowest activity (IC₅₀ value of 44 μM) and showed the lowest docking score (−8.071 kcal/mol). Finally, the pyrrolidinone rolipram was included, not only for the docking protocol validation, but also as a positive control in the enzymatic assay; rolipram was top ranked in both docking score and in vitro activity.

Compounds 1–3 and rolipram displayed a similar binding mode (Figures 3 and S5). The two predicted hydrogen bonds between the free amino group of Gln443 and the cyclopentyloxy and methoxyphenyl groups of rolipram were in agreement with the observations derived from the crystallographic structure of PDE4B in complex with rolipram. As shown, Glide found a similar hydrogen bond with Gln443 and the carboxyl group for the most active compound, 3 (Figure 3c and d); favorable π interactions with Phe446 in the binding pocket were also observed. Compounds 1 and 2 did not show hydrogen bonds with Gln433, but similar π interactions were predicted (Figures 3a, b and S5). Taken together, these observations suggested that the binding modes predicted with Glide for compounds 1–3 were reasonable.

Compounds 1–3 were assayed for cytotoxicity and antimicrobial activity. When tested against the three cancer cell lines MCF-7, H460, and SF268 (Supporting Information Table S1), compounds 2 and 3 showed moderate cytotoxicity, while 1 was inactive. Compounds 2 and 3 were equipotent against *S. aureus*, with MIC values of 25 μg/mL, while none of the compounds showed activity against *C. albicans*.




Figure 3. Binding conformation of 1 (a), 2 (b), and 3 (c) predicted by Glide. Crystallographic rolipram (maroon) is shown as a reference with hydrogen bonds displayed as yellow/black dashes. Nonpolar hydrogen atoms are omitted. (d) Two-dimensional interaction map of the optimized docking model of compound 3 in the cAMP binding pocket of PDE4B. Amino acid residues within 4.5 Å of the ligand are displayed. Blue arrows indicate hydrogen bonding to amino acid side chain atoms.

In conclusion, three compounds (1–3) were isolated and characterized from the fungus MSX 47445. The structure of the new paraquinone, 3, was assigned unequivocally by NMR and single-crystal X-ray diffraction. The effect of compounds 1–3 on the activity of PDE4B was assessed both in vitro and in silico; compound 3 was the most potent, being approximately a half-order of magnitude less potent than the positive control, rolipram. Further studies are ongoing to expand the knowledge base of this class of compounds, particularly given their compact structures.

Experimental Section

General Experimental Procedures

UV and IR spectra were acquired on a Varian Cary 100 Bio UV–vis spectrophotometer and a Perkin-Elmer Spectrum One with Universal ATR attachment, respectively. NMR experiments were conducted in either CDCl₃, acetone-d₆, or DMSO-d₆ with TMS as a reference via a JEOL ECA-500, operating at 500 MHz for ¹H and 125 MHz for ¹³C. HRESIMS was performed on a Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. UPLC was carried out on a Waters Acquity system with data collected and analyzed using

Empower software. HPLC was carried out using a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector, with data collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative HPLC, a Phenomenex Synergi Max-RP 80 (4 μ m; 250 \times 21.2 mm) column was used at a 21 mL/min flow rate, while for the semipreparative HPLC, a Phenomenex Gemini-NX C18 (4 μ m; 250 \times 10 mm) column was used at a 4.7 mL/min flow rate. For UPLC, a Waters BEH C18 column (1.7 μ m; 50 \times 2.1 mm) was used with a 0.6 mL/min flow rate. Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf using a 40 g Silica Gold column and monitored by UV and evaporative light-scattering detectors. X-ray crystallography data were acquired using a Bruker APEX CCD diffractometer (Mo K α radiation, graphite monochromator). All other reagents and solvents were obtained from Fisher Scientific and were used without further purification.

Producing Organism and Fermentation

Mycosynthetix fungal strain 47445 was isolated from highly decomposed woody debris in 1990. The growth conditions were as described previously(9, 12) and outlined in the Supporting Information. For molecular identification, the internal transcribed spacer regions 1 and 2 and 5.8S nrDNA (ITS) were sequenced, since this region of the rRNA operon has been proposed as a barcode marker for fungi.(36) Detailed methodology for DNA extraction, PCR amplification, sequencing, and phylogenetic analyses is outlined in the Supporting Information. The combined ITS and LSU sequence was deposited in GenBank (accession no. JX310275). The analyses of both the rRNA regions (ITS and D1/D2 of the LSU) suggested that MSX 47445 was a member of the Chaetothyriales, Ascomycota, and shares phylogenetic affinities with the mitosporic fungus *Cyphellophora* sp.

Extraction and Isolation

To the large-scale solid fermentation culture of MSX 47445 was added 500 mL of 1:1 MeOH–CHCl₃. The culture was chopped with a spatula and shaken overnight (~16 h) at ~100 rpm at rt. The sample was filtered with vacuum, and the remaining residues were washed with 100 mL of 1:1 MeOH–CHCl₃. To the filtrate were added 900 mL of CHCl₃ and 1500 mL of H₂O; the mixture was stirred for 2 h and then transferred into a separatory funnel. The bottom layer was drawn off and evaporated to dryness. The dried organic extract was reconstituted in 300 mL of 1:1 MeOH–CH₃CN and 200 mL of hexanes. The biphasic solution was stirred for an hour and then transferred to a separatory funnel. The MeOH–CH₃CN layer was drawn off and evaporated to dryness under vacuum. The defatted material (1.2 g, orange-red) was dissolved in a mixture of CHCl₃–MeOH, adsorbed onto Celite 545, and fractionated via flash chromatography using a gradient solvent system of hexane–CHCl₃–MeOH at a 40 mL/min flow rate and 53.3 column volumes over 63.9 min to afford seven fractions. Fraction 2 eluted with 100% CHCl₃ (~247 mg) and was subjected to preparative HPLC using an isocratic system of 55:45 CH₃CN–H₂O over 30 min at a flow rate of 4.7 mL/min to yield seven subfractions. Subfraction 5 yielded compound 1 (30.2 mg), which eluted at ~22.5 min. Subfraction 2 was subjected to semipreparative HPLC and yielded compounds 2 (12.1 mg) and 3 (6.2 mg), which eluted at 9.5 and 19.0 min, respectively. UPLC was used to evaluate the purity of 1–3 using a gradient solvent system that initiated with 20:80 CH₃CN–H₂O to 100% CH₃CN over 4.5 min; all compounds were >97% pure (Supporting Information Figure S1).

Betulinan C (3):

orange powder; UV (MeOH) λ_{max} (log ϵ) 330 (3.62), 235 (4.14), 203 (4.32) nm; IR (diamond) ν_{max} 1661, 1640, 1593, 1330, 1267, 1090, 1072, 935, 889, 849, 809, 776, 766 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) and ^{13}C NMR (CDCl_3 , 125 MHz), see Table 1; HRESIMS m/z 291.1017 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{19}\text{H}_{14}\text{O}_3$ 291.1016).

X-ray Crystallography

Crystallographic data for compound 3 have been deposited with the Cambridge Crystallographic Data Centre, deposition number 904704. Compound 3's crystals were grown in ethyl acetate at rt. X-ray crystal structure analysis of 3 were as follows: formula $\text{C}_{19}\text{H}_{13}\text{O}_3$, MW = 290.31, block-shaped yellow crystal, $a = 14.6693(18) \text{ \AA}$, $b = 7.3806(9) \text{ \AA}$, $c = 14.3582(18) \text{ \AA}$, $\beta = 115.259(1)^\circ$, $T = 193(2) \text{ K}$, $Z = 4$, monoclinic, space group $\text{P}2(1)/c$, GOF = $S = 1.043$, $V = 1405.9(3) \text{ \AA}^3$, R_1 (3088 reflections, $I > 2\sigma(I)$) = 0.0521, wR_2 (all 3719 reflections) = 0.1476, $\lambda = 0.71073 \text{ \AA}$.

Cytotoxicity Assay

The cytotoxicity measurements against the MCF-7(37) human breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H460(38) human large cell lung carcinoma (HTB-177, American Type Culture Collection (ATCC)), and SF-268(39) human astrocytoma (NCI Developmental Therapeutics Program) cell lines were performed as described previously.(40, 41)

Antimicrobial Assay

The compounds were screened for antimicrobial activity using an agar plate diffusion assay as described previously.(8)

Phosphodiesterase Inhibitor Assay

The PDE inhibitor assay was performed at BPS Bioscience Inc. as described previously.(13) Detailed experimental procedures are provided in the Supporting Information.

Molecular Modeling

Compounds 1–3 were prepared using the LigPrep 2.4 module of Maestro 9.1 (Schrödinger, LLC). The crystal structure of human PDE4B in complex with the inhibitor rolipram was retrieved from the Protein Data Bank (PDB entry 1RO6).(42) Docking was performed with the cAMP catalytic domain using the Glide (Grid-Based Ligand Docking with Energetics; Schrödinger, LLC) program, version 5.6.(35) The Protein Preparation Wizard module of Maestro was used to prepare the protein.(43) During protein preparation, H_2O molecules were deleted. For docking, the scoring grids were centered on the crystal structure of rolipram using the default bounding sizes. All structures were docked and scored using Glide.(35) The best docked poses were selected as the ones with the lowest Glide score; the more negative the Glide score, the

more favorable the binding. 2D interaction maps were generated with Discovery Studio 3.1 from Accelrys Software Inc.

Supporting Information

Information about the producing organism and its fermentation, the experimental protocol for phosphodiesterase inhibitor assay, UPLC chromatograms of compounds 1–3, ¹H and ¹³C NMR spectra for compound 3, two-dimensional interaction map of the optimized docking model of compounds 1, 2, and rolipram in the cAMP binding pocket of PDE4B, phylogram of the most likely tree, comparison between the binding position of rolipram within the crystal structure and the binding mode predicted by Glide, and cytotoxicity and antimicrobial activities of compounds 1–3. This material is available free of charge via the Internet at <http://pubs.acs.org>.

‡Author Contributions

These authors contributed equally to this work.

The authors declare no competing financial interest.

Acknowledgment

This research was supported by program project grant P01 CA125066 from the National Cancer Institute/National Institutes of Health, Bethesda, MD, USA. The high-resolution mass spectrometry data were acquired at the Triad Mass Spectrometry Laboratory at the University of North Carolina at Greensboro.

Dedication

Dedicated to Dr. Lester A. Mitscher, of the University of Kansas, for his pioneering work on the discovery of bioactive natural products and their derivatives.

References

1. Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2012**, 75, 311– 335
2. Harvey, A. L. *Drug Discovery Today* **2008**, 13, 894– 901
3. Strader, C. R.; Pearce, C. J.; Oberlies, N. H. *J. Nat. Prod.* **2011**, 74, 900– 907
4. Hanada, M.; Sugawara, K.; Kaneta, K.; Toda, S.; Nishiyama, Y.; Tomita, K.; Yamamoto, H.; Konishi, M.; Oki, T. *J. Antibiot.* **1992**, 45, 1746– 1752
5. U.S. Department of Health and Human Services U.S. Food and Drug Administration: FDA approves Kyprolis for some patients with multiple myeloma; <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312920.htm>
6. Orjala, J.; Oberlies, N. H.; Pearce, C. J.; Swanson, S. M.; Kinghorn, A. D. In *Bioactive Compounds from Natural Sources. Natural Products as Lead Compounds in Drug Discovery*, 2nd ed.; Tringali, C., Ed.; Taylor & Francis: London, UK, **2012**; pp 37– 63.
7. El-Elimat, T.; Zhang, X.; Jarjoura, D.; Moy, F. J.; Orjala, J.; Kinghorn, A. D.; Pearce, C. J.; Oberlies, N. H. *ACS Med. Chem. Lett.* **2012**, 3, 645– 649

8. Ayers, S.; Ehrmann, B. M.; Adcock, A. F.; Kroll, D. J.; Carcache de Blanco, E. J.; Shen, Q.; Swanson, S. M.; Falkinham, J. O., 3rd; Wani, M. C.; Mitchell, S. M.; Pearce, C. J.; Oberlies, N. H. *J. Pept. Sci.* **2012**, 18, 500– 510
9. Ayers, S.; Graf, T. N.; Adcock, A. F.; Kroll, D. J.; Matthew, S.; Carcache de Blanco, E. J.; Shen, Q.; Swanson, S. M.; Wani, M. C.; Pearce, C. J.; Oberlies, N. H. *J. Nat. Prod.* **2011**, 74, 1126– 1131
10. Ayers, S.; Graf, T. N.; Adcock, A. F.; Kroll, D. J.; Shen, Q.; Swanson, S. M.; Matthew, S.; Carcache de Blanco, E. J.; Wani, M. C.; Darveaux, B. A.; Pearce, C. J.; Oberlies, N. H. *J. Antibiot.* **2012**, 65, 3– 8
11. Ayers, S.; Graf, T. N.; Adcock, A. F.; Kroll, D. J.; Shen, Q.; Swanson, S. M.; Wani, M. C.; Darveaux, B. A.; Pearce, C. J.; Oberlies, N. H. *Tetrahedron Lett.* **2011**, 52, 5128–5230
12. Sy-Cordero, A. A.; Graf, T. N.; Adcock, A. F.; Kroll, D. J.; Shen, Q.; Swanson, S. M.; Wani, M. C.; Pearce, C. J.; Oberlies, N. H. *J. Nat. Prod.* **2011**, 74, 2137– 2142
13. Hawksworth, D. L. *Mycol. Res.* **1991**, 95, 641– 655
14. Blackwell, M. *Am. J. Bot.* **2011**, 98, 426– 438
15. Lee, I.-K.; Yun, B.-S.; Cho, S.-M.; Kim, W.-G.; Kim, J.-P.; Ryoo, I.-J.; Koshino, H.; Yoo, I.-D. *J. Nat. Prod.* **1996**, 59, 1090– 1092
16. Biggins, J. B.; Liu, X.; Feng, Z.; Brady, S. F. *J. Am. Chem. Soc.* **2011**, 133, 1638–1641
17. Sawayama, Y.; Tsujimoto, T.; Sugino, K.; Nishikawa, T.; Isobe, M.; Kawagishi, H. *Biosci., Biotechnol., Biochem.* **2006**, 70, 2998– 3003
18. Zhang, C.; Ondeyka, J. G.; Herath, K. B.; Guan, Z.; Collado, J.; Pelaez, F.; Leavitt, P. S.; Gurnett, A.; Nare, B.; Liberator, P.; Singh, S. B. *J. Nat. Prod.* **2006**, 69, 710– 712
19. Nakagawa, F.; Enokita, R.; Naito, A.; Iijima, Y.; Yamazaki, M. *J. Antibiot.* **1984**, 37, 6–9
20. Claveau, D.; Chen, S. L.; O’Keefe, S.; Zaller, D. M.; Styhler, A.; Liu, S.; Huang, Z.; Nicholson, D. W.; Mancini, J. A. *J. Pharmacol. Exp. Ther.* **2004**, 310, 752– 760
21. Press, N. J.; Banner, K. H. *Prog. Med. Chem.* **2009**, 47, 37– 74
22. Goldhoff, P.; Warrington, N. M.; Limbrick, D. D., Jr.; Hope, A.; Woerner, B. M.; Jackson, E.; Perry, A.; Piwnica-Worms, D.; Rubin, J. B. *Clin. Cancer Res.* **2008**, 14, 7717–7725
23. Farias, C. B.; Lima, R. C.; Lima, L. O.; Flores, D. G.; Meurer, L.; Brunetto, A. L.; Schwartzmann, G.; Roesler, R. *Oncology* **2008**, 75, 27– 31
24. Jeon, Y. H.; Heo, Y. S.; Kim, C. M.; Hyun, Y. L.; Lee, T. G.; Ro, S.; Cho, J. M. *Cell. Mol. Life Sci.* **2005**, 62, 1198– 1220
25. U.S. Department of Health and Human Services U.S. Food and Drug Administration. Approval Package For: Application Number: 022522orig1s000. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000Approval.pdf (accessed June 2, 2012) .
26. Savai, R.; Pullamsetti, S. S.; Banat, G.-A.; Weissmann, N.; Ghofrani, H. A.; Grimminger, F.; Schermuly, R. T. *Expert Opin. Invest. Drugs* **2010**, 19, 117– 131
27. Sengupta, R.; Sun, T.; Warrington, N. M.; Rubin, J. B. *Trends Pharmacol. Sci.* **2011**, 32, 337– 344
28. Wang, P.; Wu, P.; Ohleth, K. M.; Egan, R. W.; Billah, M. M. *Mol. Pharmacol.* **1999**, 56, 170– 174
29. Houslay, M. D.; Schafer, P.; Zhang, K. Y. J. *Drug Discovery Today* **2005**, 10, 1503–1519

30. Kumar, D.; Patel, G.; Vijayakrishnan, L.; Dastidar, S. G.; Ray, A. *Chem. Biol. Drug Des.* **2011**, 79, 810– 818
31. Kranz, M.; Wall, M.; Evans, B.; Miah, A.; Ballantine, S.; Delves, C.; Dombroski, B.; Gross, J.; Schneck, J.; Villa, J. P.; Neu, M.; Somers, D. O. *Bioorg. Med. Chem.* **2009**, 17, 5336–5341
32. Mpamhanga, C. P.; Chen, B.; McLay, I. M.; Ormsby, D. L.; Lindvall, M. K. *J. Chem. Inf. Model.* **2005**, 45, 1061– 1074
33. Dym, O.; Xenarios, I.; Ke, H.; Colicelli, J. *Mol. Pharmacol.* **2002**, 61, 20– 25
34. Glide, version 5.6; Schrodinger, LLC: New York, NY, **2011**.
35. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. *J. Med. Chem.* **2006**, 49, 6177– 6196
36. Schoch, C. L.; Seifert, K. A.; Huhndorf, S.; Robert, V.; Spouge, J. L.; Levesque, C. A.; Chen, W. Fungal Barcoding Consortium *Proc. Natl. Acad. Sci. U. S. A.* **2012**, 109, 6241–6246
37. Soule, H. D.; Vazquez, J.; Long, A.; Albert, S.; Brennan, M. *J. Natl. Cancer Inst.* **1973**, 51, 1409– 1416
38. Carney, D. N.; Gazdar, A. F.; Bunn, P. A., Jr.; Guccion, J. G. *Stem Cells* **1982**, 1, 149– 164
39. Rosenblum, M. L.; Gerosa, M. A.; Wilson, C. B.; Barger, G. R.; Pertuiset, B. F.; de Tribolet, N.; Dougherty, D. V. *J. Neurosurg.* **1983**, 58, 170– 176
40. Alali, F. Q.; El-Elmat, T.; Li, C.; Qandil, A.; Alkofahi, A.; Tawaha, K.; Burgess, J. P.; Nakanishi, Y.; Kroll, D. J.; Navarro, H. A.; Falkinham, J. O.; Wani, M. C.; Oberlies, N. H. *J. Nat. Prod.* **2005**, 68, 173– 178
41. Li, C.; Lee, D.; Graf, T. N.; Phifer, S. S.; Nakanishi, Y.; Riswan, S.; Setyowati, F. M.; Saribi, A. M.; Soejarto, D. D.; Farnsworth, N. R.; Falkinham, J. O., 3rd; Kroll, D. J.; Kinghorn, A. D.; Wani, M. C.; Oberlies, N. H. *J. Nat. Prod.* **2009**, 72, 1949– 1953
42. Xu, R. X.; Rocque, W. J.; Lambert, M. H.; Vanderwall, D. E.; Luther, M. A.; Nolte, R. T. *J. Mol. Biol.* **2004**, 337, 355– 365
43. Schrödinger Suite 2010 Protein Preparation Wizard, Epik version 2.1, Impact version 5.6, Prime version 2.2; Schrödinger, LLC: New York, NY, **2010**.